➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
Colorcon
McKesson
Mallinckrodt

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

Human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
Tradenames:1
Patents:9
Applicants:1
BLAs:1
Suppliers: see list2

Patent Text Search: US Patents for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant

These patents were identified by searching patent claims

Supplementary Protection Certificates for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
30/2001 Austria   Start Trial PRODUCT NAME: RECOMBINANTES HUMANES OSTEOGENES PROTEIN-1 (OP 1)
5/1996 Austria   Start Trial PRODUCT NAME: REKOMBINANTES HUMANES FOLLIKELSTIMULIERENDES HORMON
2016000049 Germany   Start Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
C/GB10/043 United Kingdom   Start Trial PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR))(HUMAN MONOCLONAL AMG 162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG 162 LIGHT CHAIN, DIMER.; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526
2018 00020 Denmark   Start Trial PRODUCT NAME: AFUCOSYLERET ANTISTOF, DER BINDER TIL ALFA-UNDERENHEDEN AF DEN HUMANE INTERLEUKIN-5-RECEPTOR, SAERLIGT BENRALIZUMAB ELLER EN TERAPEUTISK AEKVIVALENT VARIANT DERAF, SOM ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/17/1252 20180110
C/GB96/011 United Kingdom   Start Trial PRODUCT NAME: RECOMBINANT HUMAN FOLLICLE STIMULATING HORMONE; REGISTERED: FI 11529 19940815; FI 11530 19940815; UK EU/1/95/001 19951020; UK EU/1/95/002 19951020; UK EU/1/95/003 19951020; UK EU/1/95/004 19951020; UK EU/1/95/005 19951020; UK EU/1/95/006 19951020; UK EU/1/95/007 19951020; UK EU/1/95/008 19951020; UK EU/1/95/009 19951020; UK EU/1/95/010 19951020; UK EU/1/95/011 19951020; UK EU/1/95/012 19951020; UK EU/1/95/013 19951020; UK EU/1/95/014 19951020; UK EU/1/95/015 19951020; UK EU/1/95/016 19951020
C/GB94/014 United Kingdom   Start Trial PRODUCT NAME: RECOMBINANT HUMAN FACTOR- VIII (BHK); REGISTERED: NL 16789 19940419; NL 16790 19940419; NL 16791 19940419; UK 0010/0194 19940517; UK 0010/0195 19940517; UK 0010/0196 19940517
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Dow
McKesson
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.